logo
Why are some of Britain's ancient woodlands failing to regenerate?

Why are some of Britain's ancient woodlands failing to regenerate?

The Guardian10-07-2025
To the untrained eye, Monks Wood looks healthy and lush in the summer sun. Hundreds of butterflies dance on the edge of footpaths in the ancient Cambridgeshire woodland, which is rich with ash, maple and oak trees. Birds flit through the hedgerows as they feed. A fox ambles through a forest clearing, before disappearing into long grass.
But for a number of years, it has been clear to Bruno Ladvocat and Rachel Mailes that something is missing. In 2022, Ladvocat, Mailes and their research team from Birmingham University were out sampling when they noticed that the small trees that typically cover the woodland floor were increasingly hard to find.
Today, in the dappled sunshine surrounding the largest trees, spaces that would normally be home to a mass of saplings scrambling for light are bare.
This pattern is not limited to the 157-hectare (388-acre) site. From Buckholt Wood in Monmouthshire to Glen Tanar in the Cairngorms, new research across eight sites around the UK shows evidence of a deeply concerning trend: ancient woodlands are failing to regenerate.
Despite having vastly different species, soil types, rainfall and temperatures throughout the year, all the sites were following the same trend: the saplings were dying.
Mailes, a postgraduate researcher and co-author of the research, says: 'We could see as we were going through the forest that there wasn't a lot of regeneration coming back up. I had the sad job of crossing off all the saplings that we couldn't find or that we were finding dead.
'Across a lot of different species, they were just not coming back. It really made us think: there's a problem here. Then we ran all the data and we could see that we were right,' she says.
The study, which has not yet completed the peer-review process, found that sapling mortality rate increased by 90%,from 16.2% of saplings a year on average dying before 2000, increasing to 30.8% in 2022.
This means that an average sapling's chance of survival after five years has fallen from 41.3% to just 15.8%. There was also a 46% drop in the number of small trees becoming established over the same period. At two sites – Denny Wood in the New Forest and Dendles Wood on Dartmoor – no saplings at all have survived since 1995 in the sites studied.
The research is based on rare long-term monitoring of the same areas of ancient woodland since 1959, which allowed researchers to monitor changes over six decades. Its findings have sparked concern about the future resilience of Britain's forests.
Global heating, disease and overgrazing by deer could all be causing the loss. Drought and extreme heat have become commonplace in many forests. In addition, the rate of biomass loss has started to increase across the study sites, with a rise in mortality rates of the largest trees observed in some areas, rising from 0.5% to 0.8% a year.
This means that one in every 125 of the largest trees die every year instead of one in every 200. As a result, the rate at which the woodlands are removing carbon from the atmosphere has started to fall.
'I look at this as a big worry,' says Ladvocat. 'Even in areas which are relatively open, where you would expect to see new trees coming up and more trees surviving, we see less coming up and more dying.
'These forests are in a moment that makes them more vulnerable to the challenges they are facing, such as climate change and new pathogens. If there's an external force that starts killing a lot of big trees around them, then there might not be enough saplings and small trees to replace them,' he says.
Deeper into Monks Wood, we stumble across a clearing that highlights one of the many pressures in ancient woodlands: a group of ash trees, a skeletal grey, all killed off by ash dieback, a fungal disease. There is no green in the canopy, just a straight view of the blue sky above.
The disease is projected to kill up to 80% of the UK's ash trees in the coming years, and the problem is so bad in Monks Wood that researchers have to wear helmets when leaving the path to protect them from falling branches. On closer inspection, many other ash trees in the woodland are suffering from the disease.
Concerns about forests' ability to regenerate in a warming world are not new, but data is sparse and the subject is understudied, the researchers say.
'The conditions of these forests are not unlike those of other forest remnants across Great Britain and much of Europe. That's why it's concerning,' says Ladvocat. 'These changes may be more widespread than what we were able to detect with our current dataset.'
Ladvocat and Mailes are part of Membra, a project based at Birmingham University aiming to better understand how trees retain and pass on memories of stress and how this knowledge can improve resilience and management. The researchers are looking for ways to help UK woodlands reverse this worrying trend as temperatures continue to rise, bringing yet more stress.
Researchers hope they can develop methods to trigger genetic markers in seeds that make them more likely to survive. In theory, they could lead to the development of a 'bootcamp' for seedlings that could help improve forest resilience.
'There is still hope for these forests,' Ladvocat insists. 'They are still absorbing carbon; they still have lots of species that are connected to people's history. There is a possibility that this can be reversed, possibly with the help of people.'
Find more age of extinction coverage here, and follow the biodiversity reporters Phoebe Weston and Patrick Greenfield in the Guardian app for more nature coverage
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The new stage four cancer treatments and what they mean for patients
The new stage four cancer treatments and what they mean for patients

Telegraph

timean hour ago

  • Telegraph

The new stage four cancer treatments and what they mean for patients

A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden's prostate cancer was recently labelled 'aggressive' and described as having spread to his bones, many assumed the worst. Yet today, thanks to astonishing advances in cancer science, a stage-four label need not mean imminent death. 'Stage four means the cancer has spread to another part of the body further away from where it started,' explains Dr Ben O'Leary, a clinical oncologist at the Royal Marsden and a researcher at The Institute of Cancer Research (ICR). 'Most stage-four cancers still can't be cured, but our deeper understanding of how cancers evolve and grow means many people are living longer. In some cases, we now see responses, and yes, even cures, that weren't thought possible 10 years ago.' What's driving this optimism? Five types of cancer offer a snapshot of progress. Skip to: Prostate cancer Blood cancers Breast cancer Bladder cancer Lung cancer Prostate cancer By the age of 80, half of men harbour cancer in their prostate, though it proves fatal in only a small minority. Even so, around 12,000 men die of metastatic prostate cancer each year in the UK. Dr Anna Wilkins of the ICR and Royal Marsden says metastatic prostate cancer most often spreads to the bones. 'On scans, you can see up to 50 spots all over the skeleton. But there has been big progress in new drugs.' Total testosterone blockade Standard treatment reduces testosterone, the hormone that fuels tumour growth. Abiraterone, developed at the ICR, goes further by blocking its precursor hormones, extending survival significantly. Liquid radiotherapy This exciting development involves injecting patients with a radioactive liquid. Cancer cells 'drink' more of the liquid than healthy cells and the resulting burst of radiation destroys bone metastases. Liquid radiotherapy drug Radium-223 is already available on the NHS, while the even more potent Lutetium-177 PSMA is available privately and awaiting National Institute of Health and Care Excellence (Nice) appraisal. Multimodal first strikes 'We now combine hormone drugs – and sometimes chemotherapy – immediately after diagnosis,' says Dr Wilkins. Even resistant cancers respond to this approach. Treating the original tumour with radiotherapy, even in metastatic cases, also boosts survival: 'It's as if you're silencing a mothership that coordinates the metastases,' she says. While there is no cure yet, Dr Wilkins says, these approaches are turning stage-four prostate cancer into a condition many men will live with, not die from.

New brain scanner trialled in Kent could speed up dementia diagnosis
New brain scanner trialled in Kent could speed up dementia diagnosis

BBC News

time4 hours ago

  • BBC News

New brain scanner trialled in Kent could speed up dementia diagnosis

A pioneering brain scanner, one of the first to be owned by an NHS trust in England, is being trialled in Kent to improve dementia diagnosis and mental health research. The low-field MRI scanner is smaller, cheaper, and more portable than traditional machines, and could be used in community clinics for faster, more accessible by the Kent and Medway NHS and Social Care Partnership Trust (KMPT), with academic partners, the research aims to combine the scanners with AI to match the image quality of standard MRI scans. Prof Sukhi Shergill, from KMPT, believes the scanner could be "revolutionary" and lead to quicker dementia diagnosis. He said it was "currently one of the biggest challenges we face in healthcare".Experts say low-field scanners have the potential to replace standard brain scanning techniques and transform early diagnosis and treatment strategies for mental health MRI scanners often require specific power and cooling infrastructure and are sensitive to vibrations and some magnetic fields, which means they are usually housed in specially designed hospital new scanners produce lower quality images but combined with AI software they are capable of matching the image quality of larger, more expensive machines. In his role as director of research for KMPT and co-director of research at KMMSS, Prof Shergill said having smaller scanners in local communities meant they could access "almost everybody in Kent"."It's a revolutionary kind of idea to go to put these low field scanners much more locally to people," he said. It is hoped the trials would also be a be a "significant step forward in speeding up dementia assessments".Dr Joanne Rodda, a senior lecturer at Kent and Medway Medical School (KMMS) and consultant psychiatrist at KMPT, is researching the scanners' ability to help with early diagnosis of said: "Low-field scanners could potentially be offered more widely, like in community memory clinics, providing more timely results, improving patient experience." The collaboration between KMPT, KMMS, and Canterbury Christ Church University aims to support innovative research to enhance the health and well-being of communities in Kent and Medway.

French pharma giant swoops on British vaccine champion in $1.6bn deal
French pharma giant swoops on British vaccine champion in $1.6bn deal

Daily Mail​

time4 hours ago

  • Daily Mail​

French pharma giant swoops on British vaccine champion in $1.6bn deal

French pharmaceuticals giant Sanofi has agreed to acquire privately-owned British biotech firm, Vicebio, in a deal worth up to $1.6billion (£1.2billion). The deal sees Sanofi take control of Vicebio's early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). London-based Vicebio says it is 'redefining how the world combats respiratory diseases', with its 'Molecular Clamp' tech enabling the development of next-generation vaccines that offer 'broad protection, ready-to-use formulations, and high manufacturability'. Vicebio's vaccine candidate complements Sanofi's existing range, and allows it to offer a wider range to doctors and patients. The French group said on Tuesday it would pay an initial $1.15billion for the London-based respiratory diseases specialist, with a further $450million in milestone payments to be paid based on development and regulatory progress. Sanofi will also gain Vicebio's molecular clamp tech, which is used to help an immune system to recognise and respond to viral proteins more quickly. The acquisition is expected to close in the fourth quarter of 2025. Sanofi says it won't have a significant impact on its 2025 financial guidance. Jean-François Toussaint, global head of research and development vaccines at Sanofi, said: 'Vicebio's Molecular Clamp technology introduces a purposefully simple but thoughtful approach to further improve vaccine designs at a time when respiratory viral infections continue to impact millions globally. 'This acquisition furthers Sanofi's dedication to vaccine innovation with the potential to develop next-generation combination vaccines that could provide protection to older adults against multiple respiratory viruses with a single immunisation.' The acquisition follows a number of recent purchases by Sanofi, following Vigil Neuroscience in May and the DR-0201 cell engager from Dren Bio in March. rMost recently, Sanofi completed its acquisition of Blueprint Medicines last month. Emmanuel Heron, chief executive of Vicebio, said: 'Their global scale and deep expertise in vaccine development provide the ideal environment to fully realize the potential of our innovative technology. 'We look forward to advancing our platform and pipeline to deliver meaningful benefits for patients and public health.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store